Sales & Earnings In Brief
Merck consumer sales dip: Merck Consumer Care experienced a drop in first-quarter sales compared to a year ago, when, as a unit of Schering-Plough, it benefited from the launch of Claritin Liqui-Gels (1"The Tan Sheet" April 27, 2009). In the first three months of 2010, Whitehouse Station, N.J.-based Merck reported consumer sales of $379 million, down 1.3 percent. Claritin OTC sales sank 26.2 percent to $110 million in the quarter, Merck said May 4. The firm's overall quarterly results reflected effects and costs attributable to the Schering merger; net sales rose 112.1 percent to $11.42 billion, but net income dropped 77.3 percent to $330.2 million. Diluted earnings per share were off 86.6 percent to 9 cents. Merck said it expects in 2012 to begin realizing $3.5 billion in annual synergy savings
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an interview.
FDA Commissioner Martin Makary said in an interview that he will use the current structure to reform the agency. He also plans to address employee morale.
The mood at the World Vaccines Congress in Washington, D.C. was bleak given Robert F. Kennedy Jr.’s rise to lead the Trump Administration’s Health and Human Services Department, but vaccine lawyers offered an optimistic outlook and ideas for countering his vaccine agenda.